Press Releases

European Commission approves JASCAYD®, well-tolerated, novel oral treatment for IPF and PPF

[Read more](/content/human-health/lung-diseases/pulmonary-fibrosis/european-commission-approves-jascayd-novel-treatment-ipf-ppf "Read more about "European Commission approves JASCAYD®, well-tolerated, novel oral treatment for IPF and PPF""/index.html)

Boehringer strengthens obesity pipeline as potential first-in-class triple receptor agonist enters Phase II

[Read more](/content/human-health/crm-health/metabolic-health/obesity-potential-first-class-triple-receptor-agonist-phase-2 "Read more about "Boehringer strengthens obesity pipeline as potential first-in-class triple receptor agonist enters Phase II""/index.html)

Boehringer reports first-half 2026 sales growth, driven by JARDIANCE® and product launches

[Read more](/content/about-us/who-we-are/boehringer-ingelheim-half-year-results-2026 "Read more about "Boehringer reports first-half 2026 sales growth, driven by JARDIANCE® and product launches""/index.html)

Three Phase III trials in hard-to-treat cancers initiated, accelerating precision oncology

[Read more](/content/human-health/cancer/lung-cancer/three-phase-3-trials-hard-treat-cancers-initiated "Read more about "Three Phase III trials in hard-to-treat cancers initiated, accelerating precision oncology""/index.html)

FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

[Read more](/content/human-health/lung-diseases/pulmonary-fibrosis/fibroneer-trials-survival-benefit-nerandomilast-ipf-and-ppf "Read more about "FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF""/index.html)

Survodutide Phase III trial shows 34% visceral and 63% liver fat reduction while minimizing lean mass loss

[Read more](/content/human-health/crm-health/metabolic-health/survodutide-phase-3-fat-loss-obesity-dual-agonist-data "Read more about "Survodutide Phase III trial shows 34% visceral and 63% liver fat reduction while minimizing lean mass loss""/index.html)

The hidden impact of veterinary care: new insights from a global survey of veterinarians

[Read more](/content/animal-health/our-expertise/advancing-veterinary-care/hidden-impact-veterinary-care-new-insights-global-survey-veterinarians "Read more about "The hidden impact of veterinary care: new insights from a global survey of veterinarians""/index.html)

CHMP issues positive opinion for JASCAYD®, a new IPF and PPF therapy

[Read more](/content/human-health/lung-diseases/pulmonary-fibrosis/chmp-issues-positive-opinion-jascayd-ipf-and-ppf-eu "Read more about "CHMP issues positive opinion for JASCAYD®, a new IPF and PPF therapy""/index.html)

China approves HERNEXEOS® as first targeted oral treatment option

[Read more](/content/human-health/cancer/lung-cancer/china-approves-hernexeos-initial-treatment-lung-cancer "Read more about "China approves HERNEXEOS® as first targeted oral treatment option""/index.html)

Oncology portfolio shows strong promise across multiple cancers at ASCO 2026

[Read more](/content/human-health/cancer/oncology-portfolio-across-multiple-cancers-asco-2026 "Read more about "Oncology portfolio shows strong promise across multiple cancers at ASCO 2026""/index.html)

JASCAYD® approved in Japan, advancing global access to a new IPF and PPF treatment

[Read more](/content/human-health/lung-diseases/pulmonary-fibrosis/jascayd-approved-japan-new-ipf-and-ppf-treatment "Read more about "JASCAYD® approved in Japan, advancing global access to a new IPF and PPF treatment""/index.html)

Boehringer licenses Immunitas‘ novel antibody program

[Read more](/content/science-innovation/human-health-innovation/boehringer-licenses-immunitas-novel-antibody-program "Read more about "Boehringer licenses Immunitas‘ novel antibody program""/index.html)